Furthermore, pre-clinical studies have shown that anabolic pharmacological agents, such as sclerostin or DKK1 inhibitors, lead to increased bone mass and decreased osteolysis in mice with MM [15,16,17]. This evidence concerns the gene SOST and Miyoshi myopathy.